Cost-effectiveness analysis of anticoagulation options for non-valvular atrial fibrillation in Iran
Our study provides strong evidence for healthcare decision-makers in Iran, showing that apixaban is a cost-effective treatment for NVAF, potentially enhancing patient outcomes and optimizing healthcare expenditures.
Authors
- Maryam Bavandpour (ORCID: https://orcid.org/0000-0002-4856-7343)
- Satar Rezaei (ORCID: https://orcid.org/0000-0002-6194-6057)
- Mohammadreza Mobinizadeh (ORCID: https://orcid.org/0000-0003-3691-3744)
- Rajabali Daroudi (ORCID: https://orcid.org/0000-0002-0487-4114)
Institutions
- Iran University of Medical Sciences (IR)
- University of Tehran (IR)
- Kermanshah University of Medical Sciences (IR)
- Tehran University of Medical Sciences (IR)
Publication Details
- Journal
- BMC Research Notes
- Published
- 2024-11-26
- DOI
- https://doi.org/10.1186/s13104-024-07004-2
- Citations
- 1
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.40